TIDES: Oligonucleotide & Peptide Therapeutics

TIDES is the largest meeting to accelerate oligonucleotide and peptide products from early discovery to late-stage development & commercialization.

Register with VIP Code RNASOC and Save 10%!

Download the TIDES 2018 Preliminary Agenda here

Keynote Speakers

  • Robert Langer, Sc.D., Koch Institute Professor, MIT
  • Stéphane Bancel, CEO, Moderna Therapeutics
  • John Maraganore, CEO, Alnylam Pharmaceuticals
  • Jesper Lau, Ph.D., VP Protein & Peptide Chemistry, Novo Nordisk A/S

Key Themes Covered at TIDES 2018

  • Oligonucleotide Discovery, Preclinical and Clinical
    • Design oligonucleotides with better drug-like properties to advance your product from clinic to market.
  • Oligonucleotide CMC
    • Accelerate oligonucleotide product development by hearing comprehensive CMC, analytical, manufacturing and regulatory strategies for both drug substance and drug product.
  • Peptide Discovery, Preclinical and Clinical
    • Improve targeting, delivery and drug-like properties by understanding new frontiers in peptide synthesis, discovery, design and engineering.
  • Peptide CMC
    • Increase efficiency in process development, CMC, and manufacturing by understanding today’s regulatory expectations, new technologies and alternative approaches for emerging complex molecules.
  • mRNA Therapeutics
    • Learn about the latest mRNA research and development applications and CMC Strategies including regulatory insights and lessons learned from this emerging therapeutic modality.
  • CRISPR Therapeutics
    • Discover recent progress and best practices in the development of CRISPR therapeutics and genome editing from industry leaders at Editas Medicine, CRISPR Therapeutics, Intellia Therapeutics and more.